CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimer’s Association International Conference® 2022 (AAIC®). The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in San Diego, July 31- August 4, 2022.
“We’re excited to present our recent findings at AAIC which shows that 40Hz gamma sensory stimulation therapy for a 6-month period may reduce white matter atrophy, protect axons, and possibly prevent myelin and oligodendrocyte damage in Alzheimer’s patients,” said Brent Vaughan, Chief Executive Officer, Cognito Therapeutics. “Given the crucial role of white matter connecting expansive brain regions, preventing or reducing its atrophy may diminish disease progression. We look forward to sharing our results indicating that our therapy can potentially improve outcomes for patients with Alzheimer’s and Mild Cognitive Impairment, as well as other neuro-degenerative diseases that involve loss of white matter and myelination.”
Details of the presentations are as follows:
Poster Title: Gamma-Frequency Sensory Stimulation is Safe and Well-Tolerated Treatment Option for Patients with Alzheimer’s Disease
Presenting Author: Mihaly Hajós, Pharm.D., Ph.D., et al.
Date: Tuesday, August 2, 2022
Poster Title: Gamma Sensory Stimulation at 40Hz for a 6-month Period Reduces White Matter Atrophy in Alzheimer’s Disease Patients
Date: Sunday, July 31, 2022
Presenting Author: Xiao Da, M.Sc., et al.
Oral Presentation Title: Sensory stimulation improves daily functions in Alzheimer’s disease
Featured Research Session: Neuronal excitation/inhibition imbalance contributes to Alzheimer’s disease pathology and represents potential target for treatment
Presenting Author: Aylin Cimenser, Ph.D., et al.
Date/Time: Thursday, August 4, 2022, 10:30-10:45 am (PT)
To meet with the Cognito team on-site at AAIC, please contact firstname.lastname@example.org.
About Cognito Therapeutics
Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic platform has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for treatment of the cognitive and functional symptoms associated with Alzheimer's disease in individuals diagnosed with mild to moderate Alzheimer’s and expects to start pivotal studies in 2022. The company’s technology is based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and optogenetics pioneer Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx.